As per MRFR analysis, the US Parathyroid Disorders Market Size was estimated at 415.8 (USD Million) in 2023. The US Parathyroid Disorders Market Industry is expected to grow from 485.5(USD Million) in 2024 to 1,052.4 (USD Million) by 2035. The US Parathyroid Disorders Market CAGR (growth rate) is expected to be around 7.286% during the forecast period (2025 - 2035).
The US Parathyroid Disorders Market is experiencing significant trends driven by increasing awareness and diagnosis of parathyroid-related conditions. With the rise in healthcare access, more patients are being screened for disorders, leading to early detection and improved treatment outcomes.
The aging population in the US, which is more susceptible to conditions such as hyperparathyroidism, is boosting demand for relevant healthcare services and interventions. Advances in medical technology are also playing a key role, with minimally invasive surgical techniques and innovative pharmacological treatments being developed, enhancing patient care.
Opportunities are emerging as providers look to expand treatment options for parathyroid disorders. Given the increase in obesity and chronic kidney diseases, which are risk factors for parathyroid abnormalities, healthcare organizations are focusing on preventive care strategies.
The integration of digital health technologies, such as telemedicine and remote patient monitoring, is providing new avenues for patient management and follow-up. Furthermore, collaborations between pharmaceutical companies and healthcare providers are paving the way for the development of novel therapies.
In recent times, there has been a noticeable trend towards patient-centric care in the US, with a focus on tailoring treatment plans to individual needs. The demand for education and resources about parathyroid disorders is growing, prompting increased investment in community outreach and support programs.
The emphasis on outcomes measurement is also reshaping how treatments are evaluated, as stakeholders evaluate efficacy and patient satisfaction. Overall, the US Parathyroid Disorders Market is evolving through these dynamic factors, resulting in improved management of parathyroid disorders for patients nationwide.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The increasing prevalence of parathyroid disorders, particularly primary hyperparathyroidism, has become a significant driver for the growth of the US Parathyroid Disorders Market Industry. According to a study published by the National Institutes of Health, the prevalence of primary hyperparathyroidism in the United States is reported to be around 1 in 1,000 individuals, highlighting a marked increase in diagnoses over the past few decades due to improved screening and awareness.
As public health initiatives, such as those implemented by the Centers for Disease Control and Prevention, increase awareness and education regarding parathyroid disorders, more patients are likely to seek medical attention. This trend reflects an essential catalyst for market growth, as it leads to higher demand for diagnostic and therapeutic products targeting these disorders.
The aging population, particularly those aged 50 and above, is significantly more prone to these conditions, making this demographic's health management a focal point for healthcare providers and pharmaceutical companies. As a result, leading companies like Amgen and Eli Lilly & Company are actively investing in Research and Development to introduce innovative treatment options, thus enhancing the overall market landscape.
Technological advancements in diagnostic procedures are also driving the US Parathyroid Disorders Market Industry. Innovative diagnostic tools such as parathyroid hormone assays and imaging techniques are being developed to enhance the accuracy and speed of diagnosing parathyroid disorders. A report from the American Association of Clinical Endocrinologists highlights that the introduction of highly sensitive immunoassays has improved the detection rates of parathyroid-related ailments.
Furthermore, the rise of telemedicine and remote patient monitoring technologies have made it easier for patients to gain access to diagnostics without the need for physically visiting healthcare settings, thus promoting early intervention. Organizations like the American Thyroid Association are advocating for these advancements, pushing for better diagnostic access across varied demographics, which significantly benefits the market.
Such improvements in diagnostics empower healthcare professionals to manage cases efficiently and subsequently trigger higher sales for associated treatment products.
An uptick in Research and Development investments in therapies targeting parathyroid disorders is a crucial factor contributing to the growth of the US Parathyroid Disorders Market Industry. Pharmaceutical companies are striving to innovate and develop more effective treatments, driven by the increasing incidence of such disorders. According to the National Institutes of Health, funding for biomedical research aimed at understanding parathyroid biology and its implications has seen a substantial increase, amounting to several million dollars in recent years.
This influx of capital enables research entities to explore new therapeutic pathways and formulations. Leadership from organizations like the Endocrine Society emphasizes the critical need for ongoing research and supports funding initiatives, boosting the likelihood of successful outcomes and new product introductions.
As novel therapies receive regulatory approvals and enter the market, they create competitive landscapes that energize growth potentials, resulting in expanded treatment options for patients.
The growing aging population in the United States significantly impacts the US Parathyroid Disorders Market Industry, as older adults are more susceptible to various disorders, including those related to the parathyroid glands. The U.S. Census Bureau reports that by 2030, all baby boomers will be older than 65, which corresponds to an increased incidence of health issues, including osteoporosis and parathyroid disorders.
This reinforces the urgency and need for effective management solutions, directly driving market demand. The American Geriatrics Society is actively promoting awareness in treating age-related conditions, thereby increasing the consumer base for treatments related to parathyroid disorders.
As healthcare systems are increasingly focused on managing chronic diseases in older adults, pharmaceutical companies are positioned to capitalize on this demographic shift by offering tailored therapeutics targeted at this vulnerable population.
The US Parathyroid Disorders Market exhibits a notable segmentation based on the type of disorder, which significantly contributes to understanding the dynamics within the industry. The market encompasses various types of parathyroid disorders, predominantly Primary Hyperparathyroidism, Secondary Hyperparathyroidism, and Tertiary Hyperparathyroidism.
In the context of Primary Hyperparathyroidism, this condition leads to the overproduction of parathyroid hormone, often resulting in high calcium levels in the blood, which is a key health concern for many individuals in the United States. The prevalence of this disorder can be attributed to multiple factors including aging populations and increasing incidences of metabolic bone diseases.
Meanwhile, Secondary Hyperparathyroidism arises as a compensatory response to low calcium levels, commonly associated with chronic kidney disease. This condition often emerges in populations suffering from renal dysfunction, highlighting an essential health challenge as chronic kidney diseases are on the rise in the US, thus generating a need for effective treatment options.
Furthermore, Tertiary Hyperparathyroidism, which typically follows prolonged Secondary Hyperparathyroidism, represents another critical aspect of the market. Individuals with this disorder often require surgical intervention to correct the hormonal imbalance, underscoring the importance of specialized healthcare services in managing these conditions.
The current understanding of these disorders drives significant discussions around prevention and treatment strategies, and healthcare providers are increasingly focused on early diagnosis and management. The combination of different disorders within the Parathyroid Disorders Market reveals a complex landscape that reflects broader health trends in the US.
Market growth is further spurred by rising awareness of these disorders, improvements in diagnostic capabilities, and advances in treatment options, ultimately addressing a pressing healthcare need. The growing healthcare expenditure in the United States, particularly relating to chronic diseases, emphasizes the importance of addressing parathyroid disorders.
As healthcare systems adapt, there are increased opportunities for innovative treatment solutions that can manage symptoms effectively while improving patients' quality of life. Overall, the segmentation into these distinct disorders underscores the multifaceted nature of parathyroid health issues, providing a framework for market analysis and strategic planning in the US Parathyroid Disorders Market.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The Treatment Type segment of the US Parathyroid Disorders Market encompasses various approaches used to manage parathyroid disorders, which are becoming increasingly prevalent in the region. The segment is broadly categorized into Medications, Surgery, Radiation Therapy, and Observation, each playing crucial roles in patient management.
Medications often serve as a frontline therapy, providing symptomatic relief and addressing underlying metabolic abnormalities, which is essential for many patients. Surgery remains a dominant approach, particularly for those with primary hyperparathyroidism, where the removal of abnormal parathyroid tissue can lead to long-term resolution of symptoms.
Radiation Therapy is employed selectively for patients unable to undergo surgery or as adjuvant treatment, showcasing the importance of personalized care in this market. Additionally, Observation is a conservative strategy commonly utilized in cases of asymptomatic patients, reflecting a growing trend towards minimizing intervention unless necessary.
The evolving landscape highlights the significance of tailored treatment based on individual patient needs and conditions while underscoring the importance of comprehensive management strategies in the US Parathyroid Disorders Market. Overall, this segment not only addresses clinical efficacy but also aligns with ongoing advancements in medical technology and patient care protocols, ensuring optimal outcomes for affected individuals.
The Diagnosis Method segment of the US Parathyroid Disorders Market plays a critical role in the detection and management of parathyroid disorders. With advancements in medical technology, Blood Tests are becoming pivotal as they provide essential biochemical data, enabling clinicians to evaluate calcium and parathyroid hormone levels effectively.
Imaging Tests, including ultrasound and CT scans, are significant as they help in visualizing the glands and identifying any abnormal growths, aiding in precise diagnosis. Biopsies offer definitive insights by enabling pathological examination of any suspicious tissues.
The importance of these diagnostic methods is underscored by the rising prevalence of parathyroid disorders in the US, fueled by increasing awareness and advancements in diagnostic techniques. These diagnostic methods contribute substantially to the early detection and effective treatment of conditions, thus enhancing patient outcomes and driving the overall growth of the US Parathyroid Disorders Market.
As awareness continues to grow among healthcare professionals and patients alike regarding the importance of early diagnosis, the demand for these diagnostic methods is likely to witness significant momentum. The segment remains central to the market’s overall dynamics, reflecting the ongoing need for efficient and timely diagnosis in the management of parathyroid disorders.
The Patient Age Group segment within the US Parathyroid Disorders Market showcases a varied landscape that reflects the unique healthcare needs of different age cohorts. Children, often impacted by genetic disorders affecting parathyroid function, represent a crucial demographic that necessitates specialized care approaches tailored to pediatric patients.
Adults typically face parathyroid disorders linked to lifestyle factors and other health conditions, showcasing a significant prevalence in this age group, as they may experience complications associated with calcium metabolism and parathyroid hormone imbalance.
The elderly population, meanwhile, dominates this segment due to age-related conditions such as primary hyperparathyroidism, which is a common affliction impacting overall wellness and quality of life. Understanding the diverse needs across these segments enables healthcare providers to formulate effective treatment strategies and allocate resources accordingly, highlighting the importance of targeted interventions and ongoing research in the US Parathyroid Disorders Market.
As the population continues to age, the challenges and opportunities within this market segment are expected to evolve, indicating a need for healthcare innovation and adaptability.
The US Parathyroid Disorders Market has emerged as a significant segment within the broader healthcare landscape, driven by increasing prevalence of parathyroid conditions and heightened awareness among both patients and healthcare professionals. This market is characterized by a mix of established pharmaceutical companies and emerging players who are actively engaged in the development, manufacturing, and marketing of therapeutics aimed at managing parathyroid disorders.
Competitive dynamics in this sector are influenced by factors such as innovation in drug formulations, regulatory approvals, pricing strategies, and the ability to maintain a strong market presence amidst evolving healthcare policies. Companies operating within this market are constantly vying for competitive advantages, focusing on research and development to enhance their product portfolios and align with patient needs while addressing the challenges presented by generic competition and market entry barriers.
Teva Pharmaceutical Industries plays a significant role in the US Parathyroid Disorders Market, with a strong focus on providing innovative treatment options for patients suffering from these conditions. The company is known for its extensive experience in the pharmaceutical industry, which enables it to leverage its capabilities in efficiently developing therapies that target specific parathyroid issues.
Teva’s strengths lie in its established distribution networks and a reputation for manufacturing high-quality medications. Furthermore, the company has a robust pipeline of generic and branded products that cater to the needs of healthcare providers and patients alike, which positions it favourably against competitors in the US market. Its commitment to research and development emphasizes not only existing conditions but emerging therapeutic solutions, allowing the company to adapt to changing patient requirements and market conditions effectively.
Bristol Myers Squibb is another notable company within the US Parathyroid Disorders Market, distinguished by its strong focus on biopharmaceuticals and advanced therapeutic solutions. The company's involvement in parathyroid disorders is supported by an innovative portfolio that includes a range of key products benefiting patients with calcium metabolism and other related issues.
Bristol Myers Squibb has fostered its market presence through strategic mergers and acquisitions that enhance its capabilities in therapeutic development, allowing for a more extensive reach within the healthcare sector. The company's strength lies in its relentless pursuit of new scientific advancements and collaborations, which drive the development of groundbreaking therapies. By engaging in partnerships and strategic alliances, the company strengthens its market position and enhances its research capabilities, which ultimately contributes to improved patient outcomes in the realm of parathyroid disorders across the United States.
The US Parathyroid Disorders Market has seen notable advancements recently, particularly concerning drug development and therapeutic interventions. Teva Pharmaceutical Industries and AstraZeneca continue to drive innovative approaches to managing parathyroid disorders, reflecting a shift towards precision medicine.
In addition, Bristol Myers Squibb and Amgen reported substantial growth in their parathyroid-related treatments, contributing to an overall market valuation increase. During August 2023, Regeneron Pharmaceuticals made headlines for launching a clinical trial focusing on a groundbreaking therapy for Hyperparathyroidism, showcasing its commitment to enhancing patient outcomes.
Meanwhile, Eli Lilly and Company announced a partnership in July 2023 with Horizon Therapeutics to further explore treatment landscapes for parathyroid conditions, solidifying their combined market presence. Although no major mergers or acquisitions occurred specifically within these companies in recent months, the competitive landscape remains robust as firms like Zymeworks and Catalyst Pharmaceuticals strategize for market entry.
Historical developments reveal that in April 2022, MediWound expanded its research efforts, emphasizing new treatment protocols for parathyroid disorders. Overall, these movements indicate a dynamic and evolving market poised for further growth and innovation in the coming years.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 415.8(USD Million) |
| MARKET SIZE 2024 | 485.5(USD Million) |
| MARKET SIZE 2035 | 1052.4(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.286% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Million |
| KEY COMPANIES PROFILED | Teva Pharmaceutical Industries, Bristol Myers Squibb, AstraZeneca, Zymeworks, Eli Lilly and Company, Regeneron Pharmaceuticals, Horizon Therapeutics, Sarepta Therapeutics, MediWound, KalVista Pharmaceuticals, Amgen, AbbVie, Sanofi, Catalyst Pharmaceuticals, Evoke Pharma |
| SEGMENTS COVERED | Type of Disorder, Treatment Type, Diagnosis Method, Patient Age Group |
| KEY MARKET OPPORTUNITIES | Innovative treatment development, Increased diagnostic technology, Rising prevalence of disorders, Enhanced patient education initiatives, Expanding telehealth solutions |
| KEY MARKET DYNAMICS | Increasing prevalence of disorders, Advancements in diagnostic technologies, Growing research funding, Rising healthcare expenditures, Awareness of treatment options |
| COUNTRIES COVERED | US |
Frequently Asked Questions (FAQ) :
The US Parathyroid Disorders Market is expected to be valued at 485.5 million USD in 2024.
By 2035, the market is projected to reach a value of 1052.4 million USD.
The market is anticipated to grow at a CAGR of 7.286% from 2025 to 2035.
Primary Hyperparathyroidism holds the largest market share, valued at 215.0 million USD in 2024.
Secondary Hyperparathyroidism is expected to be valued at 302.0 million USD in 2035.
Key players include Teva Pharmaceutical Industries, Bristol Myers Squibb, AstraZeneca, and Eli Lilly and Company.
The market for Tertiary Hyperparathyroidism is anticipated to reach 285.4 million USD by 2035.
Key growth drivers include increasing prevalence of parathyroid disorders and advancements in treatment options.
The current market scenario presents both challenges and opportunities for growth and innovation in treatment.
Emerging trends include personalized medicine and the development of novel therapies targeting parathyroid disorders.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Analyst Explore the profile of garvit vyas, one of our esteemed authors at market research future, and access their expert research contributions in the field of market research and industry analysis
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
